K2 Therapeutics Recognized as a 2026 Endpoints 11 Honoree

K2 Therapeutics Recognized as a 2026 Endpoints 11 Honoree

BOSTON and SINGAPORE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- K2 Therapeutics (K2), a biotechnology company built for global impact, today announced that it has been named by Endpoints...

Corsera Health Named a 2026 “Endpoints 11” Honoree

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced that it has been named to the 2026 “Endpoints 11” list of the most promising startups in the biopharmaceutical industry. The annual Endpoints News honor recognizes private companies that are pursuing the most ambitious scientific breakthroughs of tomorrow, backed by expert leadership and…

Endpoints 11: Ying Huang’s K2 crew looks to marry China’s speed with global expertise

Endpoints 11 winner: Ex-Legend CEO Ying Huang is raising a $250M Series A for K2 Therapeutics, a Singapore-based hub stacked with eight China assets.